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Organ transplantation has become an increasingly important remedy 
in helping extend the lives of patients with organ failures or deficien-
cies. Although the survival rates of organ recipients have dramatically 
increased in the short term (1-5 years), long-term (5+ years) survival 
rates have not improved significantly. Additionally, increasingly un-
healthy lifestyles have contributed to a dramatic increase in the need 
for organ transplants, while organ supply has only slightly increased, 
resulting in a constantly increasing gap between organ demand and 
organ supply. Dr. Raymond Johnson, an IU Health Physician, discov-
ered a new T cell subset that is resistant to medications routinely used 
to prevent transplant rejection. This discovery is important because it 
can be used to develop mechanism-specific diagnostic blood tests for 
chronic rejection and, potentially, new drugs to treat chronic trans-
plant rejection. However, innovations developed in faculty labs often 
face multiple hurdles in reaching the market place. As participants in 
the Innovation-to-Technology Central (ITEC) program, our unique 
multidisciplinary team of students investigated Dr. Raymond Johnson’s 
discovery by conducting literature research and expert interviews on 
organ transplantation and rejection and pharmaceutical drugs used in 
preventing acute transplant rejection. Through our research and our 
interviews, we were able to further document the dire need for meth-
ods for increasing survival rates of transplanted organs.  Most im-
portantly, we have conducted preliminary market research and devel-
oped several commercialization strategy recommendations based on 
comparable innovation analysis and precedent biotechnology start-up 
strategies. We anticipate that our research will provide Dr. Johnson 
with new information and perspectives to help seek venture capitalists 
to invest in his research, which holds the promise to change the lives 
of thousands of transplant recipients each year.  
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